IPF overview diagram-2.jpg

Pulmonary fibrosis is a condition in which lung tissue becomes scarred and damaged, making it difficult for the lungs to work properly. This disease affects over 100,000 Americans at any given time, with 48,000 new cases diagnosed each year and 40,000 deaths per year. 


Currently approved methods of treatment are less than ideal and serve only slow the decline of patients' lung function. Drugs used to treat pulmonary fibrosis have many negative side effects and while lung transplants can be performed, it is a costly procedure with donor organs in short supply. 


Our Autologous Lung Spheroid Cells (LSC) Therapy provides a novel process to isolate and expand a novel source of resident lung progenitors for cell-based lung regeneration and has the potential to provide promising therapeutic treatments for pulmonary diseases involving fibrosis, degeneration, and inflammation. 


Our technology:

  • Introduces a rapid, new method to isolate and expand lung stem cells in vitro.

  • Uses a "from the lung to the lung" intrinsic stem cell strategy.

  • Eliminates the need for antigenic sorting and purification of stem cells.

  • Allows the mass manufacturing of lung stem cells to treat pulmonary diseases through lung regeneration.

  • Provides the opportunity to develop novel and effective therapeutic treatments for pulmonary and other degenerative lung diseases.